Skip to main content

Advertisement

SpringerLink
Log in

Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

The aim of this study was to analyze serum changes in mediators of fibrogenesis and in non-invasive markers of liver fibrosis among HIV/HCV-coinfected patients starting maraviroc (MVC)-based antiretroviral therapy. Patients included in this prospective pilot study met the following criteria: (1) HIV-infection, (2) detectable serum HCV-RNA, and ((3) started MVC. Transforming growth factor-β1 (TGF-beta1), matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) were measured in serum samples at baseline and 6 months after starting MVC. AST-to-platelet ratio index (APRI) was assessed at the same time points. Twenty-four patients were analyzed. Median (IQR) serum levels at baseline and after 6 months on MVC of TGF-beta1 were 27,295 (20,562–36,844) and 33,753 (18,973–46,130) pg/mL (p = 0.116), of MMP-2 were 216 (186–274) and 241 (194–306) ng/mL (p = 0.247), and of TIMP-1 were 237 (170–284) and 216 (171–271) ng/mL (p = 0.415). APRI levels were 0.99 (0.53–3.46) at baseline and 0.83 (0.48–2.34) at 6 months (p = 0.16). Serum mediators of liver fibrogenesis and fibrosis do not change significantly in HIV/HCV-coinfected patients in the short-term after starting MVC. As TGF-beta1 levels have been shown to increase over time in HCV infection and liver fibrosis worsens rapidly in HIV/HCV coinfection, these parameters seem to evolve in a different way in MVC-treated patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Merchante N, Girón-González JA, González-Serrano M et al (2006) Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 20:49–57

    Article  PubMed  Google Scholar 

  2. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL (2002) Hepatitis C and progression of HIV disease. JAMA 288:199–206

    Article  PubMed  Google Scholar 

  3. Pineda JA, García-García JA, Aguilar-Guisado M et al (2007) Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 46:622–630

    Article  PubMed  CAS  Google Scholar 

  4. Thein HH, Yi Q, Dore GJ, Krahn MD (2008) Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 15:1979–1991

    Article  Google Scholar 

  5. Macías J, von Wichmann MA, Rivero A et al (2010) Fast liver damage progression in HIV/HCV co-infected patients in spite of effective HAART. 17th Conference on Retroviruses and Opportunistic Infections. Abstract 659

  6. Berenguer J, Alvarez-Pellicer J, Martín PM et al (2009) Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 50:407–413

    Article  PubMed  CAS  Google Scholar 

  7. Mehta SH, Genberg BL, Astemborski J et al (2008) Limited uptake of hepatitis C treatment among injection drug users. J Community Health 33:126–133

    Article  PubMed  Google Scholar 

  8. Pineda JA, Mira JA, Gil Ide L, et al (2007) Influence of concomitant antiretroviral therapy on the rate of sustained virologic response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 60:1347–1354

    Article  PubMed  CAS  Google Scholar 

  9. Munshi N, Balasbramanian A, Koziel M, Ganju R, Groopman J (2003) Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. J Infect Dis 188:1192–1204

    Article  PubMed  CAS  Google Scholar 

  10. Vlahakis S, Villasis-Keever A, Gomez T, Bren GD, Paya CV (2003) Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. J Infect Dis 188:1455–1460

    Article  PubMed  CAS  Google Scholar 

  11. Huynh ML, Fadok VA, Henson PM (2002) Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 109:41–50

    PubMed  CAS  Google Scholar 

  12. Lin W, Weinberg E, Tai A et al (2008) HIV increases HCV replication in a TGF-b1-dependent manner. Gastroenterology 134:803–811

    Article  PubMed  CAS  Google Scholar 

  13. Brenner DA (2009) Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 120:361–368

    PubMed  Google Scholar 

  14. Bruno R, Galastri S, Sacchi P et al (2010) The HIV envelope protein GP120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut 59:513–520

    Article  PubMed  CAS  Google Scholar 

  15. Tuyama AC, Hong F, Saiman Y et al (2010) Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 52:612–622

    Article  PubMed  CAS  Google Scholar 

  16. Castera L, Forns X, Alberti A (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48:835–847

    Article  PubMed  Google Scholar 

  17. Neuman MG, Benhamou JP, Malkiewicz IM et al (2002) Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepatol 9:134–140

    Article  Google Scholar 

  18. Yoshiji H, Noguchi R, Kojima H et al (2006) Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C. World J Gastroenterol 12:6786–6791

    PubMed  CAS  Google Scholar 

  19. Macías J, Japón MA, Sáez C et al (2005) Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection. J Infect Dis 192:1566–1576

    Article  PubMed  Google Scholar 

  20. Bräu N, Salvatore M, Ríos-Bedoya CF et al (2006) Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 44:47–55

    Article  PubMed  Google Scholar 

  21. Macías J, Berenguer J, Japón MA et al (2009) Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 50:1056–1063

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study has been partly supported by grants from Pfizer and the Spanish Health Ministry (ISCIII-RETIC RD06/006). JAP received an intensification grant from the Fundación Progreso y Salud of the Consejería de Salud de la Junta de Andalucía (Reference AI-0021). JAP received an intensification grant from the Spanish Health Ministry (Programa-I3SNS).

Conflicts of interest

Juan Macías has been an investigator in clinical trials supported by Roche, Bristol-Myers Squibb and Abbott Pharmaceuticals. He has received lectures fees from Roche, Gilead, Boehringer Ingelheim and Bristol-Myers Squibb, and consulting fees from Boehringer Ingelheim, Bristol Myers-Squibb, Merck Sharp & Dome and Schering-Plough.

Joaquín Portilla has been an investigator in clinical trials supported by Abbott Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen Cilag, Merck Sharp & Dome and Roche. He has received lectures or consulting fees from Abbott Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen Cilag, Merck Sharp & Dome, Roche, and Schering-Plough.

Ignacio de los Santos has been an investigator in clinical trials supported by Roche, Bristol-Myers Squibb and Abbott Pharmaceuticals. He has received lecture fees from Gilead, Boehringer Ingelheim, Jansses-Cilag and Bristol-Myers Squibb, and consulting fees from Boehringer Ingelheim, Bristol Myers-Squibb, and Merck Sharp & Dome.

Antonio Rivero reports having received consulting fees from Bristol-Myers Squibb, Abbott Pharmaceuticals, Gilead, Roche and Boehringer Ingelheim.

Manuel Márquez has been an investigator in clinical trials supported by Bristol-Myers Squibb, Boehringer Ingelheim and GlaxoSmithKline. He has received lectures fees from Gilead, Boehringer Ingelheim, Jansen Cilag, Bristol-Myers Squibb, GlaxoSmithKline and Abbott Pharmaceuticals and consulting fees from Boehringer Ingelheim, Abbott Pharmaceuticals and Merck Sharp & Dome.

Juan A. Pineda reports having received consulting fees from GlaxoSmithKline, Bristol-Myers Squibb, Abbott Pharmaceuticals, Gilead, Merck Sharp & Dome, Schering-Plough, Jansen Cilag and Boehringer Ingelheim. He has received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, Abbott Pharmaceuticals and Boehringer Ingelheim and has received lecture fees from GlaxoSmithKline, Roche, Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead, Merck Sharp & Dome, Jansen Cilag, Boehringer Ingelheim and Schering-Plough.

The rest of the coauthors report no conflicts of interest.

Author information

Authors and Affiliations

  1. Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Avda. Bellavista s/n., 41014, Seville, Spain

    J. Macías, F. Di Lello, R. Mata, J. Gómez-Mateos & J. A. Pineda

  2. Servicio de Bioquímica, Hospital Universitario de Valme, Seville, Spain

    M. M. Viloria

  3. Unidad de Enfermedades Infecciosas, Hospital Universitario de Reina Sofía, Cordoba, Spain

    A. Rivero & A. Camacho

  4. Unidad de Enfermedades Infecciosas, Hospital Universitario la Princesa, Madrid, Spain

    I. de los Santos & J. Sanz-Sanz

  5. Unidad de Enfermedades Infecciosas, Hospital Universitario Virgen de la Victoria, Malaga, Spain

    M. Márquez & G. Ojeda

  6. Unidad de Enfermedades Infecciosas, Hospital General Universitario de Alicante, Alicante, Spain

    J. Portilla

Authors
  1. J. Macías
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. M. Viloria
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Rivero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. de los Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Márquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Portilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Di Lello
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Camacho
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. Sanz-Sanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G. Ojeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R. Mata
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J. Gómez-Mateos
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J. A. Pineda
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the FIBROCEL study group

Corresponding author

Correspondence to J. A. Pineda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Macías, J., Viloria, M.M., Rivero, A. et al. Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy. Eur J Clin Microbiol Infect Dis 31, 2083–2088 (2012). https://doi.org/10.1007/s10096-012-1546-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-012-1546-5

Keywords

Search

Navigation